Hamilton, Roy Hoshi;
Ciccarelli, Olga;
(2022)
Non-White Participants Matter in White Matter Disease Studies:
The Importance of Diversity in Multiple Sclerosis Clinical Trials.
Neurology
, 98
(9)
pp. 345-346.
10.1212/WNL.0000000000013224.
Preview |
Text
Ciccarelli_MS Prevalence Editorial.Draft-OC-RH-30-01-2022.pdf Download (246kB) | Preview |
Abstract
For many years, multiple sclerosis (MS) was believed to be a disease seen almost solely in White people. However, mounting evidence has made it clear that non-White individuals are equally, if not more frequently and severely, affected by MS than their White counterparts.1,2 Perhaps both a contributor to and consequence of this racial myth is the fact that non-White persons with MS are dramatically underrepresented in MS clinical trials. There is a pressing need to evaluate whether clinical trials are reflective of the diverse population that is affected by MS.
Archive Staff Only
 |
View Item |
